Crispr Therapeutics AG vs Datadog Inc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Datadog Inc trades at $243.98 (market cap $88.61B). The key difference: Datadog Inc is far larger — about 16.9× Crispr Therapeutics AG's market cap, and Datadog Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | DDOG | |
|---|---|---|
Market Cap | $5.23B | $88.61B |
Sector | Health | Technology |
52-Week High | $76.78 | $288.15 |
52-Week Low | $44.34 | $102.62 |
Enterprise Value | $3.65B | $84.90B |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →